Format

Send to

Choose Destination
Blood. 2008 Jun 15;111(12):5505-8. doi: 10.1182/blood-2007-10-114900. Epub 2008 Mar 5.

The effects of imatinib on pregnancy outcome.

Author information

1
Department of Haematology, Division of Investigative Science, Imperial College, London, United Kingdom. s.pye@imperial.ac.uk

Abstract

Imatinib has now been in use for almost 10 years. Despite this cumulative experience, little is known about its effects on pregnancy; as a result, there are few published data to facilitate the counseling of women who conceive while taking imatinib. The results we now present provide information which may be of use in such circumstances. Of 180 women exposed to imatinib during pregnancy, outcome data are available for 125 (69%). Of those with known outcomes, 50% delivered normal infants and 28% underwent elective terminations, 3 following the identification of abnormalities. There were a total of 12 infants in whom abnormalities were identified, 3 of which had strikingly similar complex malformations that are clearly a cause for concern. It appears that although most pregnancies exposed to imatinib are likely to have a successful outcome, there remains a risk that exposure may result in serious fetal malformations.

PMID:
18322153
PMCID:
PMC4916938
DOI:
10.1182/blood-2007-10-114900
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center